Genetic association of primary nonresponse to anti-TNFα therapy in patients with inflammatory bowel disease. Issue 1 (January 2022)
- Record Type:
- Journal Article
- Title:
- Genetic association of primary nonresponse to anti-TNFα therapy in patients with inflammatory bowel disease. Issue 1 (January 2022)
- Main Title:
- Genetic association of primary nonresponse to anti-TNFα therapy in patients with inflammatory bowel disease
- Authors:
- De, Tanima
Zhang, Honghong
Alarcon, Cristina
Lec, Bianca
Avitia, Juan
Smithberger, Erin
Chen, Chuyu
Horvath, Minnie
Kwan, Sara
Young, Mary
Adhikari, Sarbani
Kwon, John
Pacheco, Jennifer
Jarvik, Gail
Wei, Wei-Qi
Mentch, Frank
Hakonarson, Hakon
Sleiman, Patrick
Gordon, Adam
Harley, John
Linneman, Jim
Hebbring, Scott
Parisiadou, Loukia
Perera, Minoli A. - Abstract:
- Abstract : Objectives: Primary nonresponse (PNR) to antitumor necrosis factor-α (TNFα) biologics is a serious concern in patients with inflammatory bowel disease (IBD). We aimed to identify the genetic variants associated with PNR. Patients and methods: Patients were recruited from outpatient GI clinics and PNR was determined using both clinical and endoscopic findings. A case-control genome-wide association study was performed in 589 IBD patients and associations were replicated in an independent cohort of 293 patients. Effect of the associated variant on gene expression and TNFα secretion was assessed by cell-based assays. Pleiotropic effects were investigated by Phenome-wide association study (PheWAS). Results: We identified rs34767465 as associated with PNR to anti-TNFα therapy (odds ratio: 2.07, 95% CI, 1.46–2.94, P = 2.43 × 10 −7, [replication odds ratio: 1.8, 95% CI, 1.04–3.16, P = 0.03]). rs34767465 is a multiple-tissue expression quantitative trait loci for FAM114A2 . Using RNA-sequencing and protein quantification from HapMap lymphoblastoid cell lines (LCLs), we found a significant decrease in FAM114A2 mRNA and protein expression in both heterozygous and homozygous genotypes when compared to wild type LCLs. TNFα secretion was significantly higher in THP-1 cells [differentiated into macrophages] with FAM114A2 knockdown versus controls. Immunoblotting experiments showed that depletion of FAM114A2 impaired autophagy-related pathway genes suggesting autophagy-mediatedAbstract : Objectives: Primary nonresponse (PNR) to antitumor necrosis factor-α (TNFα) biologics is a serious concern in patients with inflammatory bowel disease (IBD). We aimed to identify the genetic variants associated with PNR. Patients and methods: Patients were recruited from outpatient GI clinics and PNR was determined using both clinical and endoscopic findings. A case-control genome-wide association study was performed in 589 IBD patients and associations were replicated in an independent cohort of 293 patients. Effect of the associated variant on gene expression and TNFα secretion was assessed by cell-based assays. Pleiotropic effects were investigated by Phenome-wide association study (PheWAS). Results: We identified rs34767465 as associated with PNR to anti-TNFα therapy (odds ratio: 2.07, 95% CI, 1.46–2.94, P = 2.43 × 10 −7, [replication odds ratio: 1.8, 95% CI, 1.04–3.16, P = 0.03]). rs34767465 is a multiple-tissue expression quantitative trait loci for FAM114A2 . Using RNA-sequencing and protein quantification from HapMap lymphoblastoid cell lines (LCLs), we found a significant decrease in FAM114A2 mRNA and protein expression in both heterozygous and homozygous genotypes when compared to wild type LCLs. TNFα secretion was significantly higher in THP-1 cells [differentiated into macrophages] with FAM114A2 knockdown versus controls. Immunoblotting experiments showed that depletion of FAM114A2 impaired autophagy-related pathway genes suggesting autophagy-mediated TNFα secretion as a potential mechanism. PheWAS showed rs34767465 was associated with comorbid conditions found in IBD patients (derangement of joints [ P = 3.7 × 10 −4 ], pigmentary iris degeneration [ P = 5.9 × 10 −4 ], diverticulum of esophagus [ P = 7 × 10 −4 ]). Conclusions: We identified a variant rs34767465 associated with PNR to anti-TNFα biologics, which increases TNFα secretion through mechanism related to autophagy. rs34767465 may also explain the comorbidities associated with IBD. Abstract : Supplemental Digital Content is available in the text. … (more)
- Is Part Of:
- Pharmaocogenetics and genomics. Volume 32:Issue 1(2022)
- Journal:
- Pharmaocogenetics and genomics
- Issue:
- Volume 32:Issue 1(2022)
- Issue Display:
- Volume 32, Issue 1 (2022)
- Year:
- 2022
- Volume:
- 32
- Issue:
- 1
- Issue Sort Value:
- 2022-0032-0001-0000
- Page Start:
- Page End:
- Publication Date:
- 2022-01
- Subjects:
- anti-TNFα -- genome-wide association study -- inflammatory bowel disease -- primary nonresponse -- single-nucleotide polymorphism
Pharmacogenetics -- Periodicals
Pharmacogenomics -- Periodicals
Genetic toxicology -- Periodicals
Biomedical genetics -- Periodicals
615.7 - Journal URLs:
- http://www.jpharmacogenetics.com ↗
http://journals.lww.com/pages/default.aspx ↗ - DOI:
- 10.1097/FPC.0000000000000445 ↗
- Languages:
- English
- ISSNs:
- 1744-6872
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6446.249100
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 25876.xml